Clear-eyed insights from a complex world

Deerfield Intelligence is the data, technology, and AI arm of Deerfield.

healthcare, not adware

We aim to identify, build, and deploy cutting-edge AI products that solve high-impact problems at the intersection of data, medicine, software, and capital.

Our team is working to develop advanced data models to uncover differentiated investment insights, surface unmet needs in healthcare, and power new product and company creation.

We strive to turn complex challenges into scalable, data-driven solutions for operators, clinicians, and portfolio companies. In addition to developing products internally, we seek to forge strategic partnerships with academic institutions, research centers, and healthcare systems to stay at the forefront of technological and scientific progress.

TEAM

Deerfield Intelligence is led by Chief Information Officer Mark Michalski, MD.

We operate as an agile enterprise at the heart of an investment firm that manages over $15B.

Meet The Team
Interpreting the Healthcare Markets

Market research for a changing world

Deerfield Intelligence analysts deliver sophisticated and timely market research to the investment team, our portfolio companies, and partners.

We use data to advance our understanding of innovations and emerging products and keep stakeholders up to date on emerging trends within the healthcare markets.

MARKET RESEARCH Capabilities Include
Epidemiology
Biostatistics
Clinical trial design and analysis
Intellectual property evaluation
Commercial market assessment
Market access (pricing, reimbursement, access)
Territory mapping
Physician targeting plans
Brand positioning and strategic planning
Forecasting
Selected Publications

We occasionally publish scientific findings in peer-reviewed journals to share insights with the scientific community and patients in need. 

Reproductive Biology and Endocrinology

A global perspective on assisted reproductive technology fertility treatment: an 8-country fertility specialist survey

Contemporary Clinical Trials Communications

Treating Clostridium difficile infections: Should fecal microbiota transplantation be reclassified from investigational drug to human tissue?

Contemporary Clinical Trials Communications

Self-reported physician practices in pulmonary arterial hypertension: diagnosis, assessment, and referral